IMR 687

Drug Profile

IMR 687

Alternative Names: IMR-687

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Developer Imara Inc
  • Class Small molecules
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sickle cell anaemia

Most Recent Events

  • 02 Feb 2017 IMR 687 receives Orphan Drug status for Sickle cell anaemia in USA
  • 16 Nov 2016 Phase-I clinical trials in Sickle cell anaemia (In volunteers) in USA (PO)
  • 14 Apr 2016 IMR 687 licensed to Imara worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top